Stock Code: 301290.SZ Stock Abbreviation: Dongxing Medical Listing Venue: Shenzhen Stock Exchange
Jiangsu Dongxing Intelligent Medical Technology Co., Ltd.
Major Asset Purchase Report
(Draft) Abstract (Revised)
| Item | Name |
|---|---|
| Counterparty to asset purchase | Bao Shijun |
| Hubei Tianhui Technology Development Co., Ltd. |
Independent Financial Advisor
Huatai United Securities Co., Ltd.
Signing Date: June 2026
Statement
The terms or abbreviations used in this section have the same meanings as those defined in the "Definitions" section of this report abstract.
I. Statement of the Listed Company
The Company and all its directors and senior management guarantee that the information disclosed by the Company is timely and fair, and that the contents of this report abstract are true, accurate, and complete, without false records, misleading statements, or major omissions. They guarantee the truth and reasonableness of the relevant data cited in this report abstract and bear corresponding legal responsibility for the truth, accuracy, and completeness of the provided information.
If the information disclosed or provided in this transaction is suspected of containing false records, misleading statements, or major omissions, and is subject to case investigation by judicial authorities or the China Securities Regulatory Commission (CSRC), the parties involved shall not transfer the shares held in the listed company until the investigation conclusion is formed. They shall submit a written application for suspension of transfer and their stock account to the board of directors of the listed company within two trading days of receiving the notice of investigation, and the board of directors shall apply for locking on their behalf to the stock exchange and the securities registration and clearing institution. If the application for locking is not submitted within two trading days, the board of directors is authorized to verify and directly report the identity and account information of the individual or entity to the stock exchange and the securities registration and clearing institution to apply for locking. If the board of directors fails to report such information, the stock exchange and the securities registration and clearing institution are authorized to lock the relevant shares directly. If the investigation concludes that there were violations, the individual or entity promises that the locked shares will be voluntarily used for relevant investor compensation arrangements.
Any decision or opinion made by the CSRC or the Shenzhen Stock Exchange regarding this transaction does not represent a substantive judgment or guarantee of the value of the Company's shares or investor returns.
In accordance with the Securities Law and other relevant laws and regulations, the Company is solely responsible for changes in its operations and earnings after the completion of this transaction, and investors are solely responsible for any investment risks arising from such changes. When evaluating this transaction, investors should carefully consider the various risk factors disclosed in this report abstract in addition to the contents of this report abstract and related documents disclosed simultaneously. If investors have any questions regarding this report abstract, they should consult their stockbroker, lawyer, accountant, or other professional advisor.
II. Statement of the Counterparty
The counterparty to this reorganization has issued a letter of commitment regarding the truth, accuracy, and completeness of the information and materials provided during the transaction process, guaranteeing that they will provide relevant information for the reorganization in a timely manner, and that the information provided for this transaction is true, accurate, and complete. If losses are caused to the listed company or investors due to false records, misleading statements, or major omissions in the provided information, they will bear compensation liability in accordance with the law.